GEMS provides a comprehensive assessment of HIV drug resistance risk with PrEP use and policy recommendations for the frequency of HIV testing and resistance monitoring for projects implementing PrEP in sub-Saharan Africa.

How will HIV drug resistance from PrEP be monitored and prevented?

Find out more at gems.pitt.edu or contact gems@pitt.edu

GEMS partners include FHI 360, BARC-Lancet Laboratories, University College London and University of Washington/Fred Hutchinson Cancer Research Center.
GEMS PROJECT GOALS

**Science**
- Comprehensively characterize resistance risk from PrEP trials and demonstration projects.

**Modeling**
- Identify the most effective and efficient HIV testing and resistance monitoring strategies.

**Policy**
- Generate evidence-based policy recommendations for HIV diagnostic testing frequency and ARV resistance monitoring.

**Rollout**
- Monitor seroconverters from PrEP roll-out programs for ARV resistance in selected clinics in countries in sub-Saharan Africa.

**GEMS** will provide technical support for HIV testing and drug resistance monitoring in PrEP programs and resistance monitoring for projects collecting dried blood spots from seroconverters on PrEP.

Find out more at gems.pitt.edu or contact gems@pitt.edu